560 related articles for article (PubMed ID: 27769061)
1. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.
Liu Y; Wan WZ; Li Y; Zhou GL; Liu XG
Oncotarget; 2017 Jan; 8(4):7181-7200. PubMed ID: 27769061
[TBL] [Abstract][Full Text] [Related]
2. Developments in selective small molecule ATP-targeting the serine/threonine kinase Akt/PKB.
Wang P; Zhang L; Hao Q; Zhao G
Mini Rev Med Chem; 2011 Nov; 11(13):1093-107. PubMed ID: 22353219
[TBL] [Abstract][Full Text] [Related]
3. Recent developments of small molecule PI3K/mTOR dual inhibitors.
Liu YN; Wan RZ; Liu ZP
Mini Rev Med Chem; 2013 Dec; 13(14):2047-59. PubMed ID: 24195664
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
Maira SM; Furet P; Stauffer F
Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
[TBL] [Abstract][Full Text] [Related]
5. ATP-competitive inhibitors of mTOR: an update.
Schenone S; Brullo C; Musumeci F; Radi M; Botta M
Curr Med Chem; 2011; 18(20):2995-3014. PubMed ID: 21651476
[TBL] [Abstract][Full Text] [Related]
6. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.
García-Echeverría C
Bioorg Med Chem Lett; 2010 Aug; 20(15):4308-12. PubMed ID: 20561789
[TBL] [Abstract][Full Text] [Related]
7. The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?
Malemud CJ
Future Med Chem; 2015; 7(9):1137-47. PubMed ID: 26132523
[TBL] [Abstract][Full Text] [Related]
8. PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence.
Narayanankutty A
Curr Drug Targets; 2019; 20(12):1217-1226. PubMed ID: 31215384
[TBL] [Abstract][Full Text] [Related]
9. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
Wu P; Hu YZ
Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
[TBL] [Abstract][Full Text] [Related]
10. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
11. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
[TBL] [Abstract][Full Text] [Related]
12. Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.
Lv X; Ma X; Hu Y
Expert Opin Drug Discov; 2013 Aug; 8(8):991-1012. PubMed ID: 23668243
[TBL] [Abstract][Full Text] [Related]
13. New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details.
Myers AP
Clin Cancer Res; 2013 Oct; 19(19):5264-74. PubMed ID: 24089439
[TBL] [Abstract][Full Text] [Related]
14. Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.
Qazi AK; Hussain A; Hamid A; Qurishi Y; Majeed R; Ahmad M; Najar RA; Bhat JA; Singh SK; Zargar MA; Ali S; Saxena AK
Anticancer Agents Med Chem; 2013 Dec; 13(10):1552-64. PubMed ID: 23438828
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
[TBL] [Abstract][Full Text] [Related]
16. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review.
Zask A; Verheijen JC; Richard DJ
Expert Opin Ther Pat; 2011 Jul; 21(7):1109-27. PubMed ID: 21591993
[TBL] [Abstract][Full Text] [Related]
18. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.
Dienstmann R; Rodon J; Serra V; Tabernero J
Mol Cancer Ther; 2014 May; 13(5):1021-31. PubMed ID: 24748656
[TBL] [Abstract][Full Text] [Related]
19. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
[TBL] [Abstract][Full Text] [Related]
20. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
